US Patent Granted for Akers' Breath Ketone Detection Device
July 17 2014 - 2:00AM
Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or
"Akers"), a leading designer and manufacturer of rapid diagnostic
screening and testing products, announces that the United States
Patent and Trademark Office ("USPTO") has granted a patent covering
Akers' Breath Ketone detection device.
The Breath Ketone detection device is based upon Akers'
proprietary MPC Biosensor Technology, which permits the rapid
identification of medical conditions through biomarkers in exhaled
breath. The primary product being developed by Akers using the
Breath Ketone detection device is the Breath Ketone "Check", which
provides real-time diagnostic information that allows diabetics
and/or their caregivers/healthcare providers to determine if they
have a severe level of ketone (acid) build up in their body. Such
ketone build up can cause a life-threatening medical emergency
called ketoacidosis.
The estimated 28.5 million Type 1 (insulin-dependent) diabetics
worldwide are at particular risk for ketoacidosis and require
routine monitoring of their ketone levels. To date the medical
industry relies on blood- and urine-based ketone testing methods,
which are invasive, inconvenient, and/or expensive. Since breath
and blood ketone levels are closely correlated, Akers' Breath
Ketone "Check" is designed to offer healthcare professionals and
their patients a convenient, accurate method, which can be
completed anytime, anywhere, to quickly determine if an
individual's ketone level is approaching a dangerous threshold
requiring medical attention.
The device has further applications in the medical and
non-medical weight management areas where the measurement of ketone
production is used to monitor the burning of body fat. In fact, the
Company is currently marketing a version of the product to weight
loss centers.
Akers is in the process of obtaining FDA 510(k) clearance for
Breath Ketone "Check" in the United States, which involves further
clinical studies to complete the regulatory submission. The Company
hopes to receive clearance in 2015.
The Company will continue the patent prosecution process for
related foreign patent applications for Akers' Breath Ketone
detection device in certain growth related jurisdictions, including
Europe and Japan.
"When developing technologies which address such huge diagnostic
markets as diabetes, having robust protection over the intellectual
property is of paramount importance for safeguarding the value of
our inventions," said Raymond F. Akers Jr., Ph.D, Executive
Chairman. "This patent grant by the USPTO has been some years in
the making and will serve as a blueprint for achieving faster
grants in other jurisdictions," continued Dr. Akers.
"We believe the ability to help Type 1 diabetics monitor their
ketone levels in a non-invasive, more convenient and less expensive
way than is currently available will be a significant advancement
in the management of a disease which affects tens of millions of
people," added Dr. Akers. "We regard Breath Ketone "Check" as one
of the Company's' high growth and cornerstone tests of the near
future; obtaining US patent approval is a critical step in the
commercialization process."
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics. Additional
information on the Company and its products can be found at
www.akersbiosciences.com.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Akers Biosciences, Inc.
Tel. +1 856 848 8698
Twitter. @AkersBio
Brendan Hopkins
RedChip Companies, Inc. (US Investor Relations)
Tel. +1 407 644 4256 x134
Emma Earl / Harrison Clarke
Daniel Stewart (Nomad and Broker)
Tel. +44 (0) 20 7776 6550
Ben Simons / Alexandra Roper
Vigo Communications (UK Investor Relations)
Tel. +44 (0) 20 7016 9570
akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024